PRECISELY Targeted Therapies for patients with cancer

With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.

Chemistry at the Core

We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.

Built for Patients

We partner with physician-scientists to identify patient needs and the limitations of existing therapies.

Driven by Purpose

We are passionate about using our expertise to address the needs of patients with cancer.

Gosia Riley
Clinical Operations
Gosia Riley
Clinical Operations
Lidya Le
Clinical Operations
Lidya Le
Clinical Operations
Jenn Fairbanks
Clinical Operations
Jenn Fairbanks
Clinical Operations
Kristin Andrews, PhD
Computational Chemistry
Kristin Andrews, PhD
Kristin Andrews, PhD
Computational Chemistry
Matthew Metivier
Human Resources
Matthew Metivier
Human Resources
Jason Kropp
Pharmaceutical Development
Jason Kropp
Jason Kropp
Pharmaceutical Development
Jessie Lin
Corporate Strategy &
Portfolio Management
Jessie Lin
Corporate Strategy &
Portfolio Management
Benjamin Lane, PhD
Technical Operations
Benjamin Lane, PhD
Benjamin Lane, PhD
Technical Operations
Christopher Cooper, PhD
Pharmaceutical Development
Christopher Cooper, PhD
Pharmaceutical Development
Sowjanya Mangipudi
Clinical Operations
Sowjanya Mangipudi
Clinical Operations
Greg Smith
Regulatory
Greg Smith
Regulatory
Yuting Sun, PhD
Biology
Yuting Sun, PhD
Biology
Joshua Horan, PhD
Chemistry
Joshua Horan, PhD
Joshua Horan, PhD
Chemistry
Tina Kehrig
Clinical Operations
Tina Kehrig
Clinical Operations
Jesus Garza
Financial Planning &
Analysis
Jesus Garza
Financial Planning &
Analysis
Darlene Noci, ALM
Chief Development Officer
Darlene Noci, ALM
Darlene Noci, ALM
Chief Development Officer
John Soglia, PhD
Translational Development
John Soglia, PhD
John Soglia, PhD
Translational Development
Nathan McConarty, JD
Legal
Nathan McConarty, JD
Legal
Kristi Byrnes
Quality Assurance
Kristi Byrnes
Quality Assurance
Morgan Maiola
Quality Assurance
Morgan Maiola
Quality Assurance
Mikhaila Ruth
Human Resources
Mikhaila Ruth
Human Resources
Joshua Lance, JD
Legal
Joshua Lance, JD
Legal
Shashank Kulkarni, PhD
Medicinal Chemistry
Shashank Kulkarni, PhD
Medicinal Chemistry
Viola Zhu, MD, PhD
Clinical Development
Viola Zhu, MD, PhD
Clinical Development
Anupong
Tangpeerachaikul, PhD
Biology
Anupong Tangpeerachaikul, PhD
Anupong
Tangpeerachaikul, PhD
Biology
Henry Pelish, PhD
Drug Discovery
Henry Pelish, PhD
Henry Pelish, PhD
Drug Discovery
Christian Martin
Translational Development
Christian Martin
Translational Development
Sibao Chen, PhD
Pharmaceutical
Development
Sibao Chen, PhD
Pharmaceutical
Development
Stephen McNamara
Finance
Stephen McNamara
Finance
Shannon Dauksis, PharmD
Program Management
Shannon Dauksis, PharmD
Program Management
Baudouin Gerard, PhD
Medicinal Chemistry
Baudouin Gerard, PhD
Baudouin Gerard, PhD
Medicinal Chemistry
James Porter, PhD
Chief Executive Officer
James Porter, PhD
James Porter, PhD
Chief Executive Officer
Scot Mente, PhD
Computational Chemistry
Scot Mente, PhD
Scot Mente, PhD
Computational Chemistry
Deb Miller, PhD, JD
Chief Legal Officer
Deb Miller, PhD, JD
Chief Legal Officer
Kari Andrews
Clinical Operations
Kari Andrews
Clinical Operations
Paula Chubet
Legal
Paula Chubet
Legal
Tuan Minh Nguyen, PhD
Biology
Tuan Minh Nguyen, PhD
Biology
Alex Balcom
Chief Financial Officer
Alex Balcom
Alex Balcom
Chief Financial Officer
Brenda Vienneau, CPA, CMA
Finance
Brenda Vienneau, CPA, CMA
Finance
Christopher Turner, MD
Chief Medical Officer
Christopher Turner, MD
Chief Medical Officer
Ray Kemper, PhD
Toxicology
Ray Kemper, PhD
Toxicology
Kevin Staffin
Quality Assurance
Kevin Staffin
Quality Assurance
Ruth Adams
Clinical Operations
Ruth Adams
Ruth Adams
Clinical Operations
Virginia Vetter
Regulatory Affairs
Virginia Vetter
Regulatory Affairs
Matthew Campbell
Pharmaceutical Development
Matthew Campbell
Pharmaceutical Development

A Phase 1/2 study of NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors.

A Phase 1/2 study of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors.

LEARN MORE ABOUT
OUR CLINICAL STUDIES